Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Shareholder Meeting (November 2025)
12 slides from Zelira Therapeutics's shareholder meeting presentation, Nov 19, 2025
Slide 1: 2025 Annual General Meeting CEO Update
ZELIRA THERAPEUTICS For personal use only 2025 Annual General Meeting CEO Update 2025 FOCUS Validating Zelira’s Operational Scale ASX: ZLD OTCQB:ZLDAF zeliratx.com
Slide 2: Disclaimer & Important Notice
DISCLAIMER & IMPORTANT NOTICE Disclaimer Future Matters For personal use only This presentation has been prepared by Zelira affairs, financial position or prospects of the Company. This presentation contains reference to certain intentions, Therapeutics Ltd ACN 103 782 378 (“Company”). The Company r
Slide 3: FY Milestones and Achievements 2025
FY Milestones and Achievements 2025 For personal use only Clinical & R&D Advancements Capital & Funding Initiatives / Publication of the IRB-approved observational study for Corporate Strengthening proprietary formulation ZLT‑L‑007 in adults with diabetic Secured an At-the-Market (ATM) equity facili
Slide 4: Zelira's Strategic Pillars - Clinical Validation First
Zelira’s Strategic Pillars - Clinical Validation First For personal use only 1 2 3 Launch Learn Develop Portfolio Approach Lifecycle Management a “proof then scale” framework Multiple shots on goal (HOPE®, ZLT-L-007, Current and pipeline Rx formulations Emphasising observational / head-to-head ZENIV
Slide 5: US FDA Clinical Trials
For personal use only US FDA Clinical Trials HOPE® 1 – Treatment of Irritability in PMS Co-morbid with Autism Spectrum Disorder (ASD)
Slide 6: FDA clinical trials and registration for HOPE drug candidate targeting ASD
FDA clinical trials and registration for its HOPE® 1 drug candidate, targeting Autism Spectrum Disorder (ASD) For personal use only Proprietary platform of Near-term development Clinically validated, highly cannabinoid medicine milestones de-risked ASD treatment HOPE® 1 is a THC:CBD oral solid Initi
Slide 7: Full pathway to US-FDA in months
Full pathway to US- FDA in 36 months FDA - Orphan designation and IND opening 1 2 3 4 5 For personal use only TPP Pre-IND Phase 1/PK Phase II Factorial & Type C Meeting 4 - 6 months Dose Ranging 8 - 10 months Solidify target Preparation and PK study in healthy Phase II trial FDA Type C Meeting produ
Slide 8: Development pathway for HOPE Phelan McDermid Syndrome program
Development pathway for HOPE® 1 Phelan McDermid Syndrome (PMS) co-morbid with ASD program Phelan-McDermid Syndrome (PMS) Regulatory Pathway For personal use only Ultra-rare genetic condition caused by a deletion or change of Accelerated regulatory pathway strategy utilising existing pre- chromosome
Slide 9: Development pathway for HOPE Phelan McDermid Syndrome program
Development pathway for HOPE® 1 Phelan McDermid Syndrome (PMS) co-morbid with ASD program For personal use only Prompt FDA response U.S. FDA responded quickly to Zelira’s Pre-IND meeting request, demonstrating the Agency’s engagement in advancing the HOPE® 1 program Positive feedback on The FDA prov
Slide 10: 2026 Outlook & Key Priorities
2026 Outlook & Key Priorities For personal use only Accelerate IND-/FDA-clinical trial pathway for HOPE® 1 in ASD/PMS indication. Advance formulation transition of ZENIVOL® into capsule format and submission for regulatory approval in Zelira’s commercial markets Initiate the advancement of ZLT-L-007
Slide 11: Global Board of Directors
Global Board of Directors For personal use only USA GLOBAL USA AUS AUS Osagie Imasogie Dr. Oludare Odumosu Dr Donna Gentile O’Donnell Tim Slate Greg Blake Chairman Global CEO Non-Executive Director Non-Executive Director Executive Director • Over 30 years in the field of • Post-clinical development
Slide 12: Thank You
For personal use only Thank You Zelira Therapeutics Phone (Australia) 1300 ZELIRA (1300 935 472) Phone (USA) +1 484 630 0650 Email info@zeliratx.com zeliratx.com
Zelira Therapeutics — Shareholder Meeting (November 2025) on 6ix